Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Core Insights - Abbott has launched its Volt™ Pulsed Field Ablation (PFA) System, aimed at treating heart rhythm disorders like atrial fibrillation (AFib) using high energy electrical pulses for ablation procedures [1][2] - The first global procedures using the Volt PFA System have been successfully conducted in Australia, with over 30 patients treated as part of a pre-market clinical study [1] - Abbott anticipates approval for its U.S. clinical trial (IDE) for the Volt PFA System in the first half of 2024 [1] Technology and Innovation - The Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing clearer indications of contact between the catheter and targeted tissue, enhancing the accuracy of ablation procedures [1][3] - The system combines the Volt PFA Catheter with Abbott's EnSite™ X EP System, allowing for precise visualization and positioning during procedures, which can lead to more efficient workflows and reduced patient exposure to radiation [3][4] - Unlike traditional methods such as radiofrequency and cryogenic ablation, the PFA technology minimizes damage to adjacent tissues, making it suitable for patients with complex cardiac conditions [2][3] Market Demand and Impact - The rise in AFib cases necessitates innovative solutions like the Volt PFA System, which aims to reduce procedure time and overall hospital stays for patients [4] - The introduction of this technology is expected to meet the growing demand for effective treatments for complex cardiac arrhythmias, improving the quality of life for millions affected by AFib [4]